RT Journal Article
SR Electronic
T1 Influence of tiotropium bromide and formoterol on bronchial hyperresponsiveness in COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3465
VO 40
IS Suppl 56
A1 Irina Trofimenko
A1 Boris Chernyak
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P3465.abstract
AB Up to 60% of COPD patients can present bronchial hyperresponsiveness (BHR) which may be a pathophysiological feature of COPD rather than a surrogate marker of airway obstruction.Aim. To evaluate an effect of a single dose tiotropium bromide (TB) and formoterol on BHR in COPD patients.Methods. 30 COPD II outpatients with BHR of mean age of 59 yrs were studied. The BHR level was analyzed initially and post-dose in 60 minutes after 18 mg TB (1-st group, n =11) and 12 mg formoterol (2-nd group, n =19). BHR was assessed in methacholine challenge.Results. A high level of BHR (provocative dose - PD20<0,04 mg) was at 40% of COPD patients, medium (PD20 0,04-0,22 mg) at 43% and low (PD20 0,23 -0,47 mg) at 17% of the surveyed initially. Pre-bronchodilators PD20 in average were comparable in both groups: 0,10 mg for the 1-st and 0,12 mg for the 2-nd group (p=0,67). BHR levels after bronchodilators were significantly less in both groups. Thus, PD20 mean values increased in 2,4 times after formoterol (p=0,0007) and in 3,6 times after TB (p= 0,0005). The number of negative tests (PD20 0,471 mg, BHR "-") in the 1-st group was more than in the 2-nd: 54,5% of patients after TB and 21,1% after formoterol (p=0,06).Conclusion: Long-acting bronchodilators – TB and formoterol after single administrations reduce BHR level in COPD patients. TB promotes more bronchoprotective effect than formoterol in COPD.